Thursday, September 18, 2025

BIOMAKERS & TOPAZIUM Unveil AI for NSCLC Immunotherapy

Related stories

Aisles Launches DREAM: AI-Driven Virtual Reality Evolution

Aisles has unveiled DREAM (Dynamic Reality Experience and Memory),...

TechSee Unveils Visual Remote Assistance with AI (VRAi) on Salesforce

TechSee, a global leader in visual customer assistance, announced...

Rendever and Lenovo Collaborate to Bring Virtual Reality Experiences to Carolina Caring Seniors

Rendever, the Boston-based company pioneering the future of aging...

Ansys 2024 R1 Reimagines the User Experience while Expanding Multiphysics Superiority Boosted by AI

The latest release from Ansys, 2024 R1, introduces an elevated user...

eXeX and Neurosurgeon Dr. Robert Masson Achieve World First Using Apple Vision Pro

eXeX™, a leader in artificial intelligence and mixed reality...
spot_imgspot_img

BIOMAKERS, a Precision Medicine & Biotech Company that supports data-driven Drug Development globally, and TOPAZIUM, an AI-driven healthtech company specializing in drug discovery and human wellbeing, have announced the results of their innovative collaborative project. This partnership showcases the power of AI systems in leveraging real-world DNA sequencing data to identify novel targets aimed at improving the efficacy of immunotherapy for non-small cell lung cancer (NSCLC) treatment. The findings were presented at the prestigious 2024 American Society of Clinical Oncology (ASCO) meeting in Chicago.

The study used Whole Exome Sequencing (WES) data from biopsies of squamous and adenocarcinoma NSCLC processed through BIOMAKERS’ advanced DNA sequencing platforms. The data was then analyzed using GFPrint™, a proprietary algorithm developed by TOPAZIUM, that generates virtual representations of tumor exomes in a latent space defined by the genetic features of the samples.

Also Read: Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

“The advent of drugs targeting the PD-1/PD-L1 axis has revolutionized NSCLC treatment. Although promising, individual responses to these therapies can vary, and we believe this ongoing project will help to better understand mechanisms involved in PD1/PD-L1 expression, optimize treatment protocols, and identify which patients are most likely to benefit from these therapies. In this study, DNA sequencing and GFPrint™ were employed to identify mutations in genes linked to PD-L1 expression in NSCLC adenocarcinoma tumor samples,” said Dr. Rubén Salanova, Chief Medical Officer & Co-Founder of BIOMAKERS.

“Using this strategy, we have identified a subpopulation of adenocarcinoma patients with increased PD-L1 expression levels, enriched in non-silent mutations of 10 genes of interest, mostly included in the HIF-1α signaling pathway. Notably, 6 of these mutated genes (PIK3R1, HK1, NOS2, NRAS, BRAF, ITGA1) were uniquely found in adenocarcinomas” said Juan Manuel Domínguez, Head of Preclinical & Biostatistics at TOPAZIUM.

“All these newly identified genes deserve further studies to validate them as potential targets for pharmacological intervention concomitant with PD-1/PD-L1 blockade, and as potential biomarkers for patient selection to improve the efficiency of immunotherapy in NSCLC treatment,” added Andrea Mendoza, Head of R&D at BIOMAKERS.

Source: Businesswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img